Our results highlight a potential role of CRY and CRYO as new chemosensitizing agents for doxorubicin chemotherapy and to re-sensitize cancer-resistant cells.
No takes yet. Share an insight, caveat, or question.
Giacomo et al. (2017) studied this question.